Welcome to

IBS-D(ECODED)

In our 3-part podcast series developed for healthcare professionals, we speak with actual IBS-D patients about their shared experiences in managing IBS-D symptoms and discuss the safety and efficacy of VIBERZI as a treatment option. As a reminder, this is not for CME/CE credit, but rather informative discussions for you and your staff to leverage when speaking with your patients about how their lives have been impacted by IBS-D.

LET’S MEET THE FACULTY

Brooks D. Cash

MD, AGAF, FACG, FACP, FASGE

Chief of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Science Center at Houston

Gregory S. Sayuk

MD, MPH

Professor of Medicine at Washington University School of Medicine, St. Louis, MO

IBS-D(ECODED) CURRICULUM

Hear from the experts (and their patients) in this 3-part peer-to-peer series.

Meet the Patient: Decoding IBS-D in Your Practice

In episode 1, our host will discuss the latest facts about IBS-D, while we meet a patient who shares her symptoms and challenges since being diagnosed a decade ago with IBS-D and hear Dr Gregory Sayuk introduce treatment options.

LISTEN TO EPISODE 1 >

Meet the Experts: Using the Symptoms to Decode IBS-D

In episode 2, our faculty discuss the extensive research and IBS-D treatment options available for healthcare providers to consider—and how this allows them to make efficient, reliable diagnosis for their patients suffering from IBS-D.

LISTEN TO EPISODE 2 >

Meet Nico & Christine: Their IBS-D Journeys Decoded

In episode 3, we meet two more patients from two very different walks of life and hear how IBS-D has impacted their well-being, while our faculty discuss their symptoms and treatment options.

LISTEN TO EPISODE 3 >

PATIENT SAVINGS PROGRAM

Savings cards available for your patients!

LEARN MORE >

VIBERZI SAMPLES

Free samples available for your patients!

ORDER HERE >

Not available where prohibited by law.

SUPPORT FOR YOU & YOUR PATIENTS

Ongoing educational updates about IBS-D!

DISCOVER MORE >

IMPORTANT SAFETY INFORMATION

Indications and Usage

VIBERZI^® (eluxadoline) CIV is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Contraindications

VIBERZI is contraindicated in patients:

Without a gallbladder.
With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
With a known hypersensitivity reaction to VIBERZI.
With severe hepatic impairment.
With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

Pancreatitis:

Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.

Sphincter of Oddi Spasm:

There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.

Hypersensitivity Reactions:

In postmarketing experience, serious hypersensitivity reactions (including anaphylaxis) have been reported following VIBERZI administration. Some of these reactions occurred after the first one or two doses of VIBERZI.
Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.

Constipation:

Constipation, sometimes requiring hospitalization, has been reported following VIBERZI administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported. Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they experience severe constipation. Avoid use with other drugs that may cause constipation.

Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Please also see full Prescribing Information.